



Rapid protein analysis and screening of membrane protein buffer conditions by gel filtration

Intellectual Property Notice: The Biopharma business of GE Healthcare was acquired by Danaher on 31 March 2020 and now operates under the Cytiva™ brand. Certain collateral materials (such as application notes, scientific posters, and white papers) were created prior to the Danaher acquisition and contain various GE owned trademarks and font designs. In order to maintain the familiarity of those materials for long-serving customers and to preserve the integrity of those scientific documents, those GE owned trademarks and font designs remain in place, it being specifically acknowledged by Danaher and the Cytiva business that GE owns such GE trademarks and font designs.

cytiva.com

GE and the GE Monogram are trademarks of General Electric Company.
Other trademarks listed as being owned by General Electric Company contained in materials that pre-date the Danaher acquisition and relate to products within Cytiva's portfolio are now trademarks of Global Life Sciences Solutions USA LLC or an affiliate doing business as Cytiva.
Cytiva and the Drop logo are trademarks of Global Life Sciences IP Holdco LLC or an affiliate.
All other third-party trademarks are the property of their respective owners.
© 2020 Cytiva
All goods and services are sold subject to the terms and conditions of sale of the supplying company operating within the Cytiva business. A copy of those terms and conditions is available on request. Contact your local Cytiva representative for the most current information.
For local office contact information, visit [cytiva.com/contact](https://www.cytiva.com/contact)

Rapid protein analysis and screening of membrane protein buffer conditions by gel filtration

Inger Salomonson¹, Said Eshaghi², Fredrik Lundström¹, and Marianne Carlsson¹

¹ GE Healthcare Bio-Sciences AB, Björkgatan 30, SE-751 84 Uppsala, Sweden

² Karolinska Institute, Stockholm, Sweden

Background

Screening of different conditions is often necessary to obtain protocols that result in pure and stable target proteins. Size-exclusion chromatography (SEC) is an excellent and gentle technique to study the state of aggregation of a protein as well as the purity of a target protein. SEC, however, is often time consuming and can also be hampered by the expense of sample and detergents. A new, small (3 ml) column format has been developed for rapid and reliable size-exclusion chromatography, employing Superdex™ 200, a powerful medium for size distribution analysis.

Column Characteristics

Column:	Tricorn™ glass column
Column dimensions:	5 mm diameter, 150 mm height
Bed volume:	3 ml
Medium:	Superdex 200
Separation range M_r :	10 000-600 000
Recommended flow rate:	0.15-0.6 ml/min
Maximum flow rate:	0.8 ml/min (245 cm/hr)
Recommended sample volume:	4-50 μ l
Max. pressure over column:	15 bar (217 psi, 1.5 MPa)



Fig 1. Tricorn columns Superdex™ 75 and Superdex 200

Conclusions

- Protein-Protein interaction studies are easily carried out using Superdex 200 5/150 GL columns.
- Screening of buffer conditions for a membrane protein was performed within a few hours and with only $6 \times 10 \mu$ l (68 μ g) sample consumption.
- Rapid purity check of an IMAC purified protein gave results similar to SDS-PAGE analysis, but in significantly less time.



Protein-Protein Interaction

To evaluate the ability of Superdex 200 5/150 GL to monitor complex formation, Trypsin and Soy Trypsin Inhibitor (STI) were analyzed. First Trypsin and STI were run separately and then a 1:1 mixture was analyzed on the gel filtration column. Only one peak eluted from the mixture of Trypsin and STI with an elution volume shifted toward the void volume, indicating interaction between Trypsin and STI (Fig 2).

Column: Superdex 200 5/150 GL
 Samples: Trypsin 1 mg/ml; Soy Trypsin Inhibitor 1 mg/ml;
 Trypsin 1 mg/ml and Soy Trypsin Inhibitor 1 mg/ml
 Sample volume: 12.5 μ l
 Buffer: PBS, pH 7.4
 Flow rate: 0.3 ml/min
 System: ÄKTAexplorer™ 10




Fig 2. Analysis of complex formation of Trypsin and Soy Trypsin Inhibitor.

Screening of buffer conditions for a membrane protein

A 60 000 M_r integral membrane protein was purified for crystallization trials. The purified protein precipitated immediately during concentration at a neutral pH. Rapid gel filtration with Superdex 200 GL 5/150 was used to screen for a stable protein under various pH and salt conditions.

Column: Superdex 200 5/150 GL
 Sample: Integral membrane protein from *E. coli*
 Sample volume: 10 μ l
 Eluents (including 0.1 or 0.3 M NaCl): 0.02 M sodium acetate, 0.03% dodecyl maltoside, 0.5 mM TCEP pH 5.2 0.02 M HEPES, 0.03% dodecyl maltoside, 0.5 mM TCEP pH 7.5 0.02 M CAPSO, 0.03% dodecyl maltoside 0.5 mM TCEP pH 9.5
 Flow rate: 0.35 ml/min
 System: ÄKTAexplorer 10




Fig 3. Screening of pH and ionic strength by gel filtration.

A symmetrical peak was observed when the separation was performed at pH 5.2 in 0.1 M NaCl (Fig 3A). This shows a homogenous size distribution of the protein under these conditions. At higher salt concentration (0.3 M NaCl, Fig 3B), a small peak appeared close to the void volume, indicating oligomerization or aggregation to a limited extent. Both at pH 7.5 and pH 9.5 (Figs 3C-F) large peaks were obtained close to the void volume, showing severe oligomerization or aggregation.

The complete screening procedure was performed in only a few hours, including the time for column equilibration. Sample consumption was $6 \times 10 \mu\text{l}$ (68 μg protein) for the complete screen. Subsequently the protein was successfully concentrated in 0.1 M NaCl at pH 5.2 for crystallization trials.

Rapid Purity Check

To achieve high purity in IMAC purifications it is often necessary to optimize the imidazol concentration in the start buffer. An extract of histidine-tagged GFP was purified on a HisTrap™ HP 1 ml column in start buffers containing 0.005, 0.01, 0.02, 0.04, and 0.06 M imidazol. The bound protein was eluted stepwise with 0.5 M imidazol (data not shown).

Immediately after the first purification was finished, the eluted peak material was pooled and analyzed on Superdex 200 5/150 in Ettan™ LC. Each analytical run was finished within 15 min. The analysis of the fractions with gel filtration showed that the purity of the fractions increased with the imidazol concentration in the start buffer (Fig 4). In this case, 0.04 M imidazol in the start buffer was recommended for the final purification of GFPHis₆ and a similar conclusion could be drawn from the analysis of the fractions by SDS-PAGE electrophoresis (Fig 5).

Column: Superdex 200 5/150 GL
Sample: fractions of purified GFP-His₆
Sample volume: 50 μl
Buffer: PBS, pH 7.4
Flow rate: 0.3 ml/min
System: Ettan LC




Fig 4. Gel filtration analysis of fractions from purification of GFP-His₆.




Fig 5. SDS-PAGE analysis of fractions from purification of GFP-His₆.

For contact information for your local office,
please visit, www.gelifesciences.com/contact

www.gelifesciences.com/protein-purification

GE Healthcare Bio-Sciences AB
Björkgatan 30
751 84 Uppsala
Sweden



imagination at work

GE, imagination at work, and GE monogram are trademarks of General Electric Company. ÄKTAexplorer, Ettan, Superdex, HisTrap, and Tricorn are trademarks of GE Healthcare companies.

The Tricorn column and components are protected by US design patents USD500856, USD506261, USD500555, USD495060 and their equivalents in other countries. This work on EGFP is done under licenses from Fisher Biolmage ApS under patent number US 6172188, Invitrogen IP Holdings Inc under patent numbers US 5777079 and US 5804387 and Columbia University under patent number US 6146826,

including foreign equivalents and pending applications. Purification and preparation of fusion proteins and affinity peptides comprising at least two adjacent histidine residues may require a license under US pat 5,284,933 and US pat 5,310,633 including foreign patents (assignee: Hoffman La Roche, Inc).

All third party trademarks are the property of their respective owners.

© 2007 General Electric Company – All rights reserved.

First published Dec. 2007.

All goods and services are sold subject to the terms and conditions of sale of the company within GE Healthcare which supplies them. A copy of these terms and conditions is available on request. Contact your local GE Healthcare representative for the most current information

GE Healthcare Limited, Amersham Place, Little Chalfont, Buckinghamshire, HP7 9NA, UK

GE Healthcare Bio-Sciences Corp., 800 Centennial Avenue, P.O. Box 1327, Piscataway, NJ 08855-1327, USA

GE Healthcare Europe GmbH, Munzinger Strasse 5, D-79111 Freiburg, Germany

GE Healthcare Bio-Sciences KK, Sanken Bldg., 3-25-1, Hyakunincho, Shinjuku-ku, Tokyo, 169-0073 Japan